Ovarian Carcinosarcoma: Clinical Trials

10 trials for Ovarian Carcinosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 10 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 5, Recruiting 3, Active not recruiting 1, Terminated 1
Phase 11Recruiting 1
Phase 31Recruiting 1

Follow Ovarian Carcinosarcoma: new trials by email Literature Review of Ovarian Carcinosarcoma trials Research Report on Ovarian Carcinosarcoma

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
VLS-1488 - Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
Phase 1 / Phase 2RecruitingVolastra Therapeutics, Inc.2002023-10-182025-11-04
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Eribulin Mesylate, Pembrolizumab - Ovarian Carcinosarcoma, Uterine Carcinosarcoma
Phase 2CompletedAustralia New Zealand Gynaecological Oncology Group132023-05-222026-08-06
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma
Phase 2RecruitingRoswell Park Cancer Institute602023-04-272026-03-23
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
Phase 2 / Phase 3RecruitingARCAGY/ GINECO GROUP1382020-07-152026-09-09
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms
Phase 2CompletedImperial College London1342018-09-212024-09-20
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma
Phase 2Active not recruitingM.D. Anderson Cancer Center302018-04-272026-11-10
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma
Phase 2TerminatedMayo Clinic172015-03-132025-12-11
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)2522009-09-082019-01-25
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Avastin, Paclitaxel, Cisplatin - Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma
Phase 2CompletedUniversity of Oklahoma202007-07-012017-07-02
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer
Phase 2CompletedNational Cancer Institute (NCI)632006-09-012015-12-07

Narrower conditions

Ovarian Neoplasms (6)  ·  Fallopian Tube Neoplasms (5)  ·  Triple Negative Breast Neoplasms (2)  ·  Bone Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Chromosomal Instability (1)  ·  Endometrial Neoplasms (1)  ·  Giant Cell Tumor of Bone (1)  ·  Histiocytoma, Malignant Fibrous (1)  ·  Osteosarcoma (1)  ·  Sarcoma (1)  ·  Somatostatinoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Thyroid Carcinoma, Anaplastic (1)

Broader conditions

Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Genital Diseases (8)  ·  Genital Diseases, Female (8)  ·  Genital Neoplasms, Female (8)  ·  Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Urogenital Diseases (8)  ·  Urogenital Neoplasms (8)  ·  Adnexal Diseases (7)  ·  Endocrine Gland Neoplasms (7)  ·  Endocrine System Diseases (7)  ·  Gonadal Disorders (7)  ·  Ovarian Diseases (7)  ·  Fallopian Tube Diseases (5)

Interventions

Bevacizumab (4)  ·  Disulfides (3)  ·  Immunoglobulin G (3)  ·  Paclitaxel (3)  ·  pembrolizumab (2)  ·  Antineoplastic Agents (1)  ·  Biopsy (1)  ·  CTLA-4 Antigen (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Gemcitabine (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  Sirolimus (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  ARCAGY/ GINECO GROUP (1)  ·  Australia New Zealand Gynaecological Oncology Group (1)  ·  Imperial College London (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)  ·  Roswell Park Cancer Institute (1)  ·  University of Oklahoma (1)  ·  Volastra Therapeutics, Inc. (1)

Countries

United States (7)  ·  Canada (3)  ·  United Kingdom (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)

Top investigators

Amir A Jazaeri (1)  ·  Amit Oza (1)  ·  Clare Scott, AM MB BS PhD (1)  ·  D. Scott McMeekin, MD (1)  ·  Emese Zsiros (1)  ·  Evanthia Galanis, M.D. (1)  ·  Henry Pitot (1)  ·  Jonathan Krell (1)

Results publications

PMID 25318437, PMID 25488966, PMID 34986897, PMID 35382842, PMID 37702588

NIH funding

N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), N01CM62208 (1)